This is a working overview of HPLC-UV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
==== 2010-2012 ==== Russian journalist Yulia Latynina stated in January 2010 that she had been told by numerous NATO military attaches that Russia had been preparing for this war for 4 years and Russian tanks entered South Ossetia before the full-scale war between Georgia and Russia. In January 2010, Russian military portal Zaotechestvo.ru published the recollections of several Russian soldiers. Aleksandr Slanov, the head of the North Ossetian regional branch of "Union of Paratroopers", the NGO of veterans of the Airborne Forces and Special Forces, said: "In the night of 4–5 August, I and five other paratroopers left for Tskhinvali. We arrived at 5 AM." Tank operator Vladimir said: "We arrived in Khetagurovo in the morning of 7 August. Our task was to destroy the Georgian fortified district, that was located on the height near Khetagurovo." Soldier Aleksandr from military special forces said that his unit was being trained for something already in July 2008 and they had to sign a paper that they voluntarily agreed to training for an indefinite period. According to Aleksandr, this meant that actually there was no drill and they were informed of the war after they were already on move. In July 2010, the Prosecutor General's Office of the Russian Federation announced that a case of Eduard Gobozov, employee of the Ministry of Defence of the Republic of South Ossetia, was sent to the court in North Ossetia. Gobozov was accused of treason.
==== HIV/AIDS ==== In 2013, scientists have been investigating an alternative approach to treating HIV-1/AIDS, based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1-resistant) hematopoietic stem and progenitor cells (GM-HSPC).
In 2021, Pansino hosted the HBO Max series Baketopia where contestants competed in a bake-off to win up to $10,000; her hosting work on the show received praise and she also executive produced several episodes. In November 2024, Pansino started her own podcast series called the "Rodiculous Podcast", where she has interviews and conversations with celebrities and fellow YouTubers, with a lot of them being her friends.
Radiocarbon dating has established that the shroud is medieval, and not from the time of Jesus. Independent radiocarbon dating tests were carried out in 1988 at the University of Oxford, the University of Arizona and the Swiss Federal Institute of Technology, following years of discussion to obtain permission from the Holy See. The tests were done on portions of a swatch taken from a corner of the shroud, and concluded with 95% confidence that the material dated to AD 1260–1390. The dating matches the first appearance of the shroud in church history. This dating is also slightly more recent than that estimated by the art historian W. S. A. Dale, who postulated on artistic grounds that the shroud is an 11th-century icon made for use in worship services. Some proponents for the authenticity of the shroud have attempted to discount the radiocarbon dating result by claiming that the sample may represent a medieval "invisible mending" repair fragment rather than the image-bearing cloth. However, all of the hypotheses used to challenge the radiocarbon dating have been scientifically refuted, including the medieval repair hypothesis, the bio-contamination hypothesis and the carbon monoxide hypothesis. In recent years, the radiocarbon dating data have been repeatedly statistically analysed in attempts to draw some conclusions about the reliability of the radiocarbon dating from studying the data rather than studying the shroud itself.
In April 2024, Panera launched a major menu overhaul marketed as the "New Era at Panera," which the company described as the most significant menu transformation in its history. The update involved discontinuing categories such as flatbread pizzas and grain bowls to refocus on core offerings like soups, salads, and sandwiches. The change introduced over 20 new or enhanced items with larger portions and lower price points in a strategic effort to improve value and increase customer traffic. On February 14, 2025, Ken Rosenthal, the founder of St. Louis Bread Company, died at age 81 due to complications from Alzheimer's disease. In March 2025, the company named Paul Carbone its new CEO. In July 2025, it was announced that the company was continuing a move begun in 2024 to a "par-baked" model for its restaurants, closing down existing dough-making facilities, and laying off employees. This model has restaurants receive partially-baked ("Par-baked") frozen bread which is finished in the store instead of freshly baked every day. The company has also been reportedly rolling back their "clean food guidelines" which previously advocated for stances against antibiotics and hormones, and for animal welfare.
Sources: en.wikipedia.org
On 17 October 1971, Gajowniczek was a special guest of Pope Paul VI in the Vatican when Maximilian Kolbe was beatified for his martyrdom. In 1972, Time magazine reported that over 150,000 people made a pilgrimage to Auschwitz to honor the anniversary of Kolbe's beatification. One of the first to speak was Gajowniczek, who declared "I want to express my thanks for the gift of life." His wife, Helena, died in 1977. Gajowniczek was in the Vatican once again, this time as a guest of Pope John Paul II, when Kolbe was canonized on 10 October 1982. In 1994, Gajowniczek visited St. Maximilian Kolbe Catholic Church of West Chester, Pennsylvania and also in Houston, Texas, where he told his translator Chaplain Thaddeus Horbowy that "so long as he ... has breath in his lungs, he would consider it his duty to tell people about the heroic act of love by Maximilian Kolbe." Gajowniczek died in the city of Brzeg on 13 March 1995 at the age of 93. He was buried at Niepokalanów, a religious community founded by Maximilian Kolbe, 53 years after Kolbe saved his life. He was survived by his second wife, Janina.
The citric acid cycle is regulated mainly by the availability of key substrates, particularly the ratio of NAD+ to NADH and the concentrations of calcium, inorganic phosphate, ATP, ADP, and AMP. Citrate – the ion that gives its name to the cycle – is a feedback inhibitor of citrate synthase and also inhibits PFK, providing a direct link between the regulation of the citric acid cycle and glycolysis.
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
=== Other procedures === More recent approaches to the synthesis of N-substituted isatins involves the direct oxidation of commercially available, substituted indoles or oxindoles with different oxidizing agents such as TBHP, IBX-SO3K, tBuONO etc.
Jimmy John's Franchise, LLC, commonly referred to as Jimmy John's, is an American multinational sandwich chain, headquartered in Champaign, Illinois. The business was founded by Jimmy John Liautaud in 1983. After Liautaud graduated from high school, his father gave him a choice to either join the military or start a business. Liautaud decided to start a hot dog business, which changed to sandwiches due to costs. The Jimmy John's chain has over 2,800 locations, with 98% of them being franchises. In 2016, Roark Capital Group purchased a majority stake in the company. Later, in 2019, Inspire Brands purchased the company from Roark Capital Group for an unspecified amount.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.